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The global threat of the emerging yellow fever disease can be effectively countered by vaccination. First 
vaccines against yellow fever have been developed in embryonated chicken eggs in the 1930s and this 
production platform remained almost unchanged until today. However, recent outbreaks revealed vaccine 
supply shortages due to limiting options to ramp up production. 
 
Here, we present a cell culture-based process using EB66® cells for production of a live, attenuated yellow fever 
vaccine (YFV; WHO 17D-213/77 strain). The duck embryo-derived EB66® suspension cell line showed good 
growth performance in batch mode achieving up to 1.8 × 107 cells/mL and doubling times of less than 17 h in 
shake flasks in the chemically-defined CDM4Avian medium at 37°C. The seed virus material was adapted by 
five serial passages to the cell substrate, which resulted in an 8-fold increase in virus titer to 1.3 × 108 PFU/mL 
(infectious virions per mL). Changes in process temperature and cell disruption to facilitate virus release did not 
improve final virus titers. In a next step, the process was transferred into benchtop bioreactors equipped with an 
alternating tangential flow filtration unit (ATF2) operating at a working volume of 700 mL. An on-line conductivity 
probe was implemented, which enabled cell growth monitoring in real-time. This setup allowed to achieve high 
cell densities of up to 9.5 × 107 cells/mL resulting in a further increase of YFV titers up to 7.3 × 108 PFU/mL. 
Based on an input of 4.7 log infectious units per dose, raw virus material equivalent to 10 Mio vaccine doses 
was produced in less than two weeks operation time. 
 
Taken together, EB66® suspension cells can grow to very high cell densities in perfusion systems. Present 
process intensification clearly demonstrated the potential to produce millions of YFV vaccine doses from small 
scale cultures in a controllable and scalable manner. 
 
